Available And Emerging Therapies For Progressive/Recurrent ROS1-Altered Advanced NSCLC CCO Oncology podcast

Innhold levert av Clinical Care Options, LLC and Clinical Care Options. Alt podcastinnhold, inkludert episoder, grafikk og podcastbeskrivelser, lastes opp og leveres direkte av Clinical Care Options, LLC and Clinical Care Options eller deres podcastplattformpartner. Hvis du tror at noen bruker det opphavsrettsbeskyttede verket ditt uten din tillatelse, kan du følge prosessen skissert her https://no.player.fm/legal.

CCO Oncology Podcast »
Available and Emerging Therapies for Progressive/Recurrent ROS1-Altered Advanced NSCLC

10d ago 13:53

Del

MP3•Episoder hjem

In this episode, listen to Alice T. Shaw, MD, PhD, and Jessica J. Lin, MD, share their thoughts on the available and emerging clinical data for second-line and beyond treatments in patients with recurrent ROS1-altered advanced NSCLC including:

Assessing ROS1-TKI resistance mutations with tumor and liquid biopsies in patients with ROS1-altered advanced NSCLC
Previous TKI-treated cohort from the TRIDENT-1 study: efficacy of repotrectinib in patients with recurrent ROS1-altered NSCLC and measurable baseline brain metastases
Phase II TRUST-1 trial of taletrectinib: activity in patients with known ROS1 G2032R resistance mutation ROS1-altered advanced NSCLC
The global phase I/II ARROS-1 study of zidesamtinib (NVL-520): safety summary in patients with ROS1-altered advanced NSCLC

Program faculty:

Jessica J. Lin, MD
Attending Physician
Massachusetts General Hospital
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Alice T. Shaw, MD, PhD
Chief, Strategic Partnerships
Attending Physician, Thoracic Oncology
Dana-Farber Cancer Institute
Harvard Medical School
Boston, Massachusetts

Resources:
To download the slides associated with this podcast discussion, please visit the program page.

181 episoder

#Science #Fitness #Biology #Higher Education #Podcasting Education #Medicine #Clinical Care Options, LLC #Clinical Care Options #Essential Thrombocythemia #Myelofibrosis #Oncology #CME #Nonmalignant Hematological Disorders #Skin Cancer #Hematological Malignancies #Acute Myeloid Leukemia #Kidney Cancer #Melanoma #Gastrointestinal Cancer #Acute Lymphocytic Leukemia #Prostate Cancer #Myeloproliferative Neoplasms #Follicular Lymphoma #Glioblastoma #Nsclc #Multiple Myeloma #Hodgkin Lymphoma #Basal Cell Carcinoma #All #Polycythemia Vera #Breast Cancer #Dlbcl #Head And Neck Cancer #Liver Cancer #Sarcoma #Gastroesophageal Cancer #Lung Cancer #Hepatocellular Carcinoma #Urothelial Carcinoma #Cancer Screening #Renal Cell Carcinoma #AML #Ovarian Cancer #CPE #Lymphoma #Diffuse Large B-cell Lymphoma #Cll #Pancreatic Cancer #Beta-thalassemia #Chronic Myeloid Leukemia